國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Therapeutic drug monitoring dataa co...

Dasgupta, Amitava, (1958-)

Therapeutic drug monitoring dataa concise guide /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Therapeutic drug monitoring dataAmitava Dasgupta, Matthew D. Krasowski.
其他題名:	a concise guide /
作者:	Dasgupta, Amitava,
其他作者:	Krasowski, Matthew D.,
出版者:	London, United Kingdom ;Academic Press,2020.
面頁冊數:	1 online resource.
附註:	6.2 Drug-herb interactions
標題:	Drug monitoring.
電子資源:	https://www.sciencedirect.com/science/book/9780128158494
ISBN:	9780128158500 (electronic bk.)

Therapeutic drug monitoring dataa concise guide /
Dasgupta, Amitava,1958-

Therapeutic drug monitoring dataa concise guide /[electronic resource] :Amitava Dasgupta, Matthew D. Krasowski. - Fourth edition. - London, United Kingdom ;Academic Press,2020. - 1 online resource.

6.2 Drug-herb interactions

Includes bibliographical references and index.

Front Cover; Therapeutic Drug Monitoring Data: A Concise Guide; Copyright; Contents; Preface; Chapter 1: Pharmacokinetics and therapeutic drug monitoring; 1.1 Introduction; 1.2 Compliance and TDM; 1.3 Basic pharmacokinetics; 1.3.1 Liberation; 1.3.2 Absorption; 1.3.3 Distribution; 1.3.4 Binding of drugs with serum proteins; 1.3.5 Metabolism; 1.3.6 Excretion; 1.3.7 Pharmacokinetic calculations; 1.3.8 Clearance; 1.4 Therapeutic ranges; 1.5 Guidelines for TDM; 1.6 Specialpopulation and TDM; 1.6.1 Drug disposition in uremia; 1.6.2 Drug disposition in hepatic disease

ISBN: 9780128158500 (electronic bk.)Subjects--Topical Terms:

646781
Drug monitoring.
Index Terms--Genre/Form:

214472
Electronic books.

LC Class. No.: RM301.9 / .D37 2020

Dewey Class. No.: 615.7

Therapeutic drug monitoring dataa concise guide /
LDR:03853cmm a2200325 a 4500 001 601569
006 m o d
007 cr cnu---unuuu
008 211110s2020 enka gob 001 0 eng d
020 $a 9780128158500 (electronic bk.)
020 $a 0128158506 (electronic bk.)
020 $a 9780128158494
020 $a 0128158492
035 $a (OCoLC)1120690888
035 $a on1120690888
040 $a EBLCP $b eng $c EBLCP $d OCLCQ $d YDXIT $d OCLCF $d OCLCQ
041 0 $a eng
050 4 $a RM301.9 $b .D37 2020
082 0 4 $a 615.7 $2 23
100 1 $a Dasgupta, Amitava, $d 1958- $3 646780
245 1 0 $a Therapeutic drug monitoring data $h [electronic resource] : $b a concise guide / $c Amitava Dasgupta, Matthew D. Krasowski.
250 $a Fourth edition.
260 $a London, United Kingdom ; $a San Diego, CA : $b Academic Press, $c 2020.
300 $a 1 online resource.
500 $a 6.2 Drug-herb interactions
504 $a Includes bibliographical references and index.
505 0 $a Front Cover; Therapeutic Drug Monitoring Data: A Concise Guide; Copyright; Contents; Preface; Chapter 1: Pharmacokinetics and therapeutic drug monitoring; 1.1 Introduction; 1.2 Compliance and TDM; 1.3 Basic pharmacokinetics; 1.3.1 Liberation; 1.3.2 Absorption; 1.3.3 Distribution; 1.3.4 Binding of drugs with serum proteins; 1.3.5 Metabolism; 1.3.6 Excretion; 1.3.7 Pharmacokinetic calculations; 1.3.8 Clearance; 1.4 Therapeutic ranges; 1.5 Guidelines for TDM; 1.6 Specialpopulation and TDM; 1.6.1 Drug disposition in uremia; 1.6.2 Drug disposition in hepatic disease
505 8 $a 1.6.3 Drug disposition in cardiovascular diseases1.6.4 Drug disposition in critically ill patients; 1.6.5 Drug disposition in thyroid diseases; 1.7 Conclusions; References; Chapter 2: Before and after: The pre-analytical and post-analytical phases of TDM; 2.1 Introduction; 2.2 Proper timing of specimen collection; 2.3 Issues with blood collection tubes; 2.4 Processing and storage of specimens; 2.5 Troubleshooting; References; Chapter 3: Clinical utility of monitoring free drug levels; 3.1 Introduction; 3.2 Binding of drugs with serum proteins
505 8 $a 3.3 Drugs requiring free drug monitoring3.4 When to monitor free drug concentration?; 3.5 Monitoring free anticonvulsant concentration; 3.5.1 Clinical utility of monitoring free phenytoin concentrations; 3.5.2 Clinical utility of monitoring free valproic acid concentration; 3.5.3 Clinical utility of monitoring free carbamazepine concentrations; 3.6 Drugs bound to alpha-1-acid glycoprotein and free drug monitoring; 3.7 Monitoring free concentrations of immunosuppressants; 3.8 Monitoring free concentrations of protease inhibitors; 3.9 Special situation: Monitoring free digoxin
505 8 $a 3.10 Saliva for monitoring of free drug concentration3.11 Methods for monitoring free drug concentration; 3.12 Conclusions; References; Chapter 4: Effects of bilirubin, lipemia, hemolysis, paraproteins and heterophilic antibodies onimmunoassays for therapeu ... ; 4.1 Introduction; 4.2 Bilirubin interferences in immunoassays used for TDM; 4.3 Interference due to hemolysis; 4.4 Lipid interference; 4.5 Interferences from protein and paraproteins; 4.6 Interferences from heterophilic antibodies; 4.7 Biotin interferences in TDM; 4.8 Conclusions; References
505 8 $a Chapter 5: Application of chromatographic techniques for therapeutic drug monitoring5.1 Introduction; 5.2 Limitations of immunoassays; 5.3 Overview of chromatographic methods; 5.4 High-performance liquid chromatography methods; 5.5 Gas chromatography methods; 5.6 Liquid chromatography coupled to mass spectrometry; 5.7 Challenges with liquid chromatography tandem mass spectrometry systems; 5.8 Therapeutic drug monitoring applications; 5.9 Future directions; References;Chapter 6: Drug-herb and drug-food interactions and effects on therapeutic drug monitoring; 6.1 Introduction
650 0 $a Drug monitoring. $3 646781
655 4 $a Electronic books. $2 local. $3 214472
700 1 $a Krasowski, Matthew D., $e author. $3 896794
856 4 0 $u https://www.sciencedirect.com/science/book/9780128158494